Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.
FTC and DOJ propose changes that could slow dealmaking review process
The Federal Trade Commission and Justice Department have proposed changes to the merger review process that could extend the amount of time and documentation it
June 30, 2023